Compositions and methods for detecting diseases in cattle using extracellular vesicles

The use of cattle-derived extracellular vesicles for identifying unique proteins in BRD diagnosis addresses the inadequacies of current methods, enabling accurate and targeted treatment of bovine respiratory disease.

WO2026236460A1PCT designated stage Publication Date: 2026-11-12BOARD OF REGENTS FOR THE OKLAHOMA AGRI & MECHANICAL COLLEGE ACTING FOR & ON BEHALF OF OKLAHOMA STATE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027059
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current diagnostic methods for bovine respiratory disease (BRD) in cattle are inadequate, leading to economic losses due to untreated infections and the development of drug-resistant bacterial strains, as they lack a reliable molecular diagnostic method for early pathogen detection.

Method used

Utilizing extracellular vesicles (EVs) isolated from cattle serum to identify unique proteins derived from bacterial pathogens and differentially expressed bovine proteins as novel biomarkers for BRD diagnosis, enabling accurate detection through mass spectrometry and antibody-based assays.

Benefits of technology

Provides a reliable method for early detection of BRD, reducing the use of antimicrobials and minimizing the risk of drug-resistant strains by identifying specific pathogen and host proteins in EVs, thereby guiding targeted treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000031_0000
    Figure 00000031_0000
  • Figure 00000031_0001
    Figure 00000031_0001
  • Figure 00000031_0002
    Figure 00000031_0002
Patent Text Reader

Abstract

Compositions, kits, and systems are utilized for detecting at least one molecular biomarker in an extracellular vesicle of a cattle subject for detection of bovine respiratory disease (BRD). Methods of performing the detection assay are also disclosed. The biomarkers may be from a pathogen or from host-derived proteins that are upregulated in response to the infection.
Need to check novelty before this filing date? Find Prior Art

Description

ELECTRONICALLY TRANSMITTED: May 7, 2026 PCTCOMPOSITIONS AND METHODS FOR DETECTING DISEASES IN CATTLE USING EXTRACELLULAR VESICLESCROSS REFERENCE TO RELATED APPLICATIONS / INCORPORATION BY REFERENCE STATEMENT

[0001] The subject application claims benefit under 35 USC § 119(e) of US Provisional Application No. 63 / 801,217, filed May 7, 2025. The entire contents of the above-referenced patent application(s) are hereby expressly incorporated herein by reference.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] Not Applicable.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

[0003] The instant application contains, as a separate part of the present disclosure, a Sequence Listing which has been submitted via WIPO-Sequence in computer readable form as an XML file. The Sequence Listing, created May 7, 2026, is named "57910276wo_Sequence_Listing.xml" and is 6,185,962 bytes in size. The entire contents of the Sequence Listing are hereby incorporated herein by reference.BACKGROUND

[0004] Bovine respiratory disease (BRD), historically known as shipping fever, is a "multifactorial syndrome" caused by bacterial and viral infections. This disease is one of the largest reasons for economic loss in the beef and dairy industries causing 70 - 80% and 40 - 50% of feedlot-morbidity and -mortality, respectively, in the United States. Collectively, BRD treatment, reduced animal performance, feed efficiency, and end product value all contribute to economic loss. Various factors such as weaning stress, transportation, and environmental change can weaken the immune system and make cattle more susceptible to BRD. While all cattle can develop BRD, animals that are newly introduced into the feedlot are at the highest risk of BRD. It has been reported that BRD can be caused by various bacterial species, such as (but not limited to) Mannheimia haemolytica,Pasteurella multocida, Histophilus somni, and Mycoplasma bovis (Edwards, Vet Clin North Am Food Anim Pract (2010) 26:273-284; Gaudino et al., Veterinary Research (2022) 53:70).

[0005] Considering the impact of BRD on cattle industries, an effective prevention strategy, including vaccination, good management practices, and early pathogen detection, are essential for mitigating the economic loss associated with BRD (Bushby et al., Scientific Reports (2024) 14:9737; Centeno-Martinez et al., Animal Microbiome (2022) 4:15; Wilson et al., J Anim Sci (2017) 95:2170-2182). The symptoms for BRD can include nasal discharge, decreased appetite, lethargy, labored breathing, depression, poor body condition, and a rectal temperature greater than 39.7°C (Duff and Galyean, Journal of Animal Science (2007) 85:823-840; Wilson et al., J Anim Sci (2015) 93:3661-3674). A simple diagnostic procedure for BRD, known as the depression, appetite, respiration, and temperature (DART) system, is based on clinical symptoms and guides antimicrobial treatment for BRD in feedlot cattle (Step et aL, J Anim Sci (2008) 86:3146-3158; Wilson et al., J Anim Sci (2015) 93:3661-3674). To effectively control BRD in feedlot cattle, an early diagnostic method that can accurately identify microbial pathogens is essential. Moreover, a reliable molecular diagnostic method for BRD will help reduce the use of antimicrobials, thereby minimizing the risk of developing drug-resistant bacterial strains in both cattle and humans.

[0006] Extracellular vesicles (EVs) are nanoscale membrane particles that are released by various cell types into the extracellular space. Released EVs carry proteins, DNA, RNA and lipids derived from the cells of origin (Cheng and Schorey, 2020. Chapter 6- The function and therapeutic use of exosomes in bacterial infections. In Exosomes. L. Edelstein, et al., editors. Academic Press, 123-146.; Schorey et al., EMBO reports (2021) 16:24-43; Vermeire et al., Proteomics (2024) e202400181). EVs have been isolated from various human and animal body fluids, including blood, urine, milk, and saliva (Schorey et al., Journal of Cell Science (2021) 134; Schorey et al., EMBO reports (2015) 16:24-43). Interestingly, the composition of EVs is altered by various disease states. For example, in the context of infectious diseases, EVs released by host cells infected with bacterial pathogens, such as Mycobacterium tuberculosis, not only carry host molecules but also mycobacterial components, including bacterial proteins, RNA and lipids (Cheng and Schorey, EMBO reports (2019) 20:e46613; Schorey et al., EMBO reports (2021) 16:24-43). Therefore, EVs have been studied for their application as novel biomarkers for the diagnosis of human and animal diseases (Kumar et al., Signal Transduction and Targeted Therapy (2024) 9:27; Schorey et al., EMBO reports(2021) 16:24-43). However, EVs have not been utilized successfully as diagnostic tools for cattle diseases.BRIEF DESCRIPTION OF THE DRAWINGS

[0007] FIG. 1 illustrates characterization of purified MVs. (A) NanoSight analysis for EVs isolated from healthy or sick cattle with the symptom of BRD. (B) EV yield from healthy or sick cattle with the symptom of BRD. Total EV yield was determined by NanoSight NS300 and values were calculated based on the volume of cattle serum used for vesicle isolation. (C) Total protein abundance in purified EVs. The results in (B) and (C) are mean ± SD (n=5 / group). n.s., not significant. *p < 0.05 by two-tailed Student's t test.

[0008] FIG. 2 illustrates a summary of unique bovine protein numbers in EVs isolated from healthy or sick cattle with the symptom of BRD.DETAILED DESCRIPTION

[0009] Certain non-limiting embodiments of the present disclosure are directed to compositions and kits as well as methods of producing and using said compositions and kits for detecting bovine respiratory disease (BRD) in cattle.

[0010] Before explaining at least one embodiment of the inventive concept(s) in detail by way of exemplary language and results, it is to be understood that the inventive concept(s) is not limited in its application to the details of construction and the arrangement of the components set forth in the following description. The inventive concept(s) is capable of other embodiments or of being practiced or carried out in various ways. As such, the language used herein is intended to be given the broadest possible scope and meaning; and the embodiments are meant to be exemplary - not exhaustive. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

[0011] Unless otherwise defined herein, scientific and technical terms used in connection with the presently disclosed inventive concept(s) shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The foregoing techniques and procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughoutthe present specification. The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses and chemical analyses.

[0012] All patents, published patent applications, and non-patent publications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this presently disclosed inventive concept(s) pertains. All patents, published patent applications, and non-patent publications referenced in any portion of this application are herein expressly incorporated by reference in their entirety to the same extent as if each individual patent or publication was specifically and individually indicated to be incorporated by reference.

[0013] All of the compositions and / or methods disclosed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of the inventive concept(s) have been described in terms of particular embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and / or methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit, and scope of the inventive concept(s). All such similar substitutions and modifications apparent to those skilled in the art are deemed to be within the spirit, scope, and concept of the inventive concept(s) as defined by the appended claims.

[0014] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0015] The use of the term "a" or "an" when used in conjunction with the term "comprising" in the claims and / or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." As such, the terms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "a compound" may refer to one or more compounds, two or more compounds, three or more compounds, four or more compounds, or greater numbers of compounds. The term "plurality" refers to "two or more."

[0016] The use of the term "at least one" will be understood to include one as well as any quantity more than one, including but not limited to, 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 100, etc. The term "at least one" may extend up to 100 or 1000 or more, depending on the term to which it is attached; in addition, the quantities of 100 / 1000 are not to be considered limiting, as higher limitsmay also produce satisfactory results. In addition, the use of the term "at least one of X, Y, and Z" will be understood to include X alone, Y alone, and Z alone, as well as any combination of X, Y, and Z. The use of ordinal number terminology (i.e., "first," "second," "third," "fourth," etc.) is solely for the purpose of differentiating between two or more items and is not meant to imply any sequence or order or importance to one item over another or any order of addition, for example.

[0017] The use of the term "or" in the claims is used to mean an inclusive "and / or" unless explicitly indicated to refer to alternatives only or unless the alternatives are mutually exclusive. For example, a condition "A or B" is satisfied by any of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

[0018] As used herein, any reference to "one embodiment," "an embodiment," "some embodiments," "one example," "for example," or "an example" means that a particular element, feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. The appearance of the phrase "in some embodiments" or "one example" in various places in the specification is not necessarily all referring to the same embodiment, for example. Further, all references to one or more embodiments or examples are to be construed as non-limiting to the claims.

[0019] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for a composition / apparatus / device, the method being employed to determine the value, or the variation that exists among the study subjects. For example, but not by way of limitation, when the term "about" is utilized, the designated value may vary by plus or minus twenty percent, or fifteen percent, or twelve percent, or eleven percent, or ten percent, or nine percent, or eight percent, or seven percent, or six percent, or five percent, or four percent, or three percent, or two percent, or one percent from the specified value, as such variations are appropriate to perform the disclosed methods and as understood by persons having ordinary skill in the art.

[0020] As used in this specification and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include"), or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0021] The term "or combinations thereof" as used herein refers to all permutations and combinations of the listed items preceding the term. For example, "A, B, C, or combinations thereof" is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.

[0022] As used herein, the term "substantially" means that the subsequently described event or circumstance completely occurs or that the subsequently described event or circumstance occurs to a great extent or degree. For example, when associated with a particular event or circumstance, the term "substantially" means that the subsequently described event or circumstance occurs at least 80% of the time, or at least 85% of the time, or at least 90% of the time, or at least 95% of the time. For example, the term "substantially adjacent" may mean that two items are 100% adjacent to one another, or that the two items are within close proximity to one another but not 100% adjacent to one another, or that a portion of one of the two items is not 100% adjacent to the other item but is within close proximity to the other item.

[0023] As used herein, the phrases "associated with" and "coupled to" include both direct association / binding of two moieties to one another as well as indirect association / binding of two moieties to one another. Non-limiting examples of associations / couplings include covalent binding of one moiety to another moiety either by a direct bond or through a spacer group, non-covalent binding of one moiety to another moiety either directly or by means of specific binding pair members bound to the moieties, incorporation of one moiety into another moiety such as by dissolving one moiety in another moiety or by synthesis, and coating one moiety on another moiety, for example.

[0024] The term "pharmaceutically acceptable" refers to compounds and compositions which are suitable for administration to humans and / or animals without undue adverse side effects, such as (but not limited to) toxicity, irritation, and / or allergic response, commensurate with a reasonable benefit / risk ratio.

[0025] The term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include, but are not limited to, individualsalready having a particular condition / disease / infection as well as individuals who are at risk of acquiring a particular condition / disease / infection (e.g., those needing prophylactic / preventative measures). The term "treating" refers to administering an agent to a subject / patient for therapeutic and / or prophylactic / preventative purposes.

[0026] A "therapeutic composition" or "pharmaceutical composition" refers to an agent that may be administered in vivo to bring about a therapeutic and / or prophylactic / preventative effect.

[0027] Administering a therapeutically effective amount or prophylactically effective amount is intended to provide a therapeutic benefit in the treatment, prevention, and / or management of a disease, condition, and / or infection. The specific amount that is therapeutically effective can be readily determined by the ordinary medical practitioner, and can vary depending on factors known in the art, such as (but not limited to) the type of condition / disease / infection, the patient's history and age, the stage of the condition / disease / infection, and the co-administration of other agents.

[0028] The term "effective amount" refers to an amount of a biologically active molecule or sufficient to exhibit a detectable therapeutic effect without undue adverse side effects (such as (but not limited to) toxicity, irritation, and allergic response) commensurate with a reasonable benefit / risk ratio when used in the manner of the inventive concept(s). The therapeutic effect may include, for example but not by way of limitation, preventing, inhibiting, or reducing the occurrence of infection by or growth of microbes and / or opportunistic infections. The effective amount for a subject will depend upon the type of subject, the subject's size and health, the nature and severity of the condition / disease / infection to be treated, the method of administration, the duration of treatment, the nature of concurrent therapy (if any), the specific formulations employed, and the like. Thus, it is not possible to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by one of ordinary skill in the art using routine experimentation based on the information provided herein.

[0029] As used herein, the term "concurrent therapy" is used interchangeably with the terms "combination therapy," "combinatorial therapy," and "adjunct therapy," and will be understood to mean that the patient in need of treatment is treated or given another drug for the disease / infection in conjunction with the compositions of the present disclosure. This concurrent therapy can be sequential therapy, where the patient is treated first with one composition and then the other composition, or the two compositions are given simultaneously (either in the same or different formulations).

[0030] The terms "administration" and "administering," as used herein, will be understood to include all routes of administration known in the art. In addition, the compositions of the present disclosure (and / or the methods of administration of same) may be designed to provide delayed, controlled, or sustained release using formulation techniques which are well known in the art.

[0031] The term "pharmaceutically acceptable carrier or excipient" includes any carriers or excipients known in the art may be utilized in accordance with the present disclosure. For example (but not by way of limitation), a physiological compatible carrier (e.g., saline) that is compatible with maintaining the structure / activity of the active ingredient(s) when administered, and compatible with the desired mode of administration, may be utilized as the pharmaceutically acceptable carrier in accordance with the present disclosure. In addition, the active ingredient(s) may be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient(s). Suitable excipients include, for example but not by way of limitation, water, saline, dextrose, glycerol, ethanol, and the like, or any combination thereof.

[0032] The term "sample" as used herein will be understood to include any type of biological sample that may be utilized in accordance with the present disclosure. Examples of fluidic biological samples that may be utilized include, but are not limited to, whole blood or any portion thereof (i.e., plasma or serum), urine, saliva, sputum, cerebrospinal fluid (CSF), skin, intestinal fluid, intraperitoneal fluid, cystic fluid, sweat, interstitial fluid, extracellular fluid, tears, mucus, bladder wash, semen, fecal, pleural fluid, nasopharyngeal fluid, combinations thereof, and the like.

[0033] The term "antibody" is used in the broadest sense, and specifically (but not by way of limitation) covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), fragments of any of the above, and conjugates of any of the above, so long as they exhibit the desired biological activity of analyte binding. Thus, the term "antibody" or "antibody peptide(s)" refers to a full-length immunoglobulin molecule (i.e., an intact antibody) or an antigen-binding fragment thereof that competes with the intact antibody for specific antigen binding. Antigen-binding fragments may be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Antigenbinding fragments include Fab, Fab', F(ab')2, Fv, scFv, disulfide linked Fv, Fd, diabodies, single-chain antibodies, single domain antibodies (such as but not limited to, NANOBODIES®), and otherantibody fragments or conjugates thereof that retain at least a portion of the variable region of an intact antibody, antibody substitute proteins or peptides (i.e., engineered binding proteins / peptides), andcombinations or derivatives thereof. See, e.g., Hudson et al. (Nature Med. (2003) 9:129-134). The antibody can be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or sub-class (e.g., IgGl, lgG2, lgG3, lgG4, IgAl, and lgA2).

[0034] The term "antigen binding fragment" or "antigen-binding portion" of an antibody, as used herein, refers to one or more fragments of an antibody that retain the ability to bind to an antigen. The antigen-binding function of an antibody can be performed by fragments of an intact antibody. Examples of binding fragments encompassed within the term "antigen-binding fragment" of an antibody include but are not limited to, Fab, Fab', F(ab')2, Fv, scFv, disulfide linked Fv, Fd, diabodies, single-chain antibodies, single domain antibodies (such as but not limited to, NANOBODIES®), isolated CDRH3, and other antibody fragments that retain at least a portion of the variable region of an intact antibody. These antibody fragments are obtained using conventional recombinant and / or enzymatic techniques and are screened for antigen binding in the same manner as intact antibodies.

[0035] An "antibody heavy chain," as used herein, refers to the larger of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformations.

[0036] An "antibody light chain," as used herein, refers to the smaller of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformations. Kappa and lambda light chains refer to the two major antibody light chain isotypes.

[0037] The terms "CDR," and its plural "CDRs," refer to a complementarity determining region (CDR) of an antibody or antibody fragment, which determine the binding character of an antibody or antibody fragment. In most instances, three CDRs are present in a light chain variable region (CDRL1, CDRL2 and CDRL3) and three CDRs are present in a heavy chain variable region (CDRH1, CDRH2 and CDRH3). CDRs contribute to the functional activity of an antibody molecule and are separated by amino acid sequences that comprise scaffolding or framework regions. Among the various CDRs, the CDR3 sequences, and particularly CDRH3, are the most diverse and therefore have the strongest contribution to antibody specificity. There are at least two techniques for determining CDRs: (1) an approach based on cross-species sequence variability (i.e., Kabat et al., Sequences of Proteins of Immunological Interest (National Institute of Health, Bethesda, Md. (1987), incorporated by reference in its entirety); and (2) an approach based on crystallographic studies of antigenantibody complexes (Chothia et al., Nature, 342:877 (1989), incorporated by reference in its entirety).

[0038] The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin orT-cell receptor. In certain embodiments, an epitope is a region of an antigen that is specifically bound by an antibody. Epitopic determinants usually include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, or sulfonyl groups. In certain embodiments, an epitope may have specific three-dimensional structural characteristics (e.g., a "conformational epitope"), as well as specific charge characteristics.

[0039] An epitope is defined as "the same" as another epitope if a particular antibody specifically binds to both epitopes. In certain embodiments, polypeptides having different primary amino acid sequences may comprise epitopes that are the same. In certain embodiments, epitopes that are the same may have different primary amino acid sequences. Different antibodies are said to bind to the same epitope if they compete for specific binding to that epitope.

[0040] An antibody "specifically binds" an antigen when it preferentially recognizes the antigen in a complex mixture of proteins and / or macromolecules. In certain embodiments, an antibody comprises an antigen-binding site that specifically binds to a particular epitope. In certain such embodiments, the antibody is capable of binding different antigens so long as the different antigens comprise that particular epitope or closely related epitopes. In certain instances, for example, homologous proteins from different species may comprise the same epitope. In certain embodiments, an antibody specifically binds to an antigen with a dissociation constant of no greater than 10-6 M, 10-7 M, 10-8 M, or 10-9 M. When an antibody specifically binds to a receptor or ligand (i.e., counterreceptor), it may substantially inhibit adhesion of the receptor to the ligand. As used herein, an antibody substantially inhibits adhesion of a receptor to a ligand when an excess of antibody reduces the quantity of receptor bound to ligand by at least about 20%, 40%, 60%, 80%, 85%, or 90% (as measured in an in vitro competitive binding assay).

[0041] An "isolated" antibody is one which has been separated and / or recovered from a component of the environment in which it was produced. Contaminant components of its production environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In certain embodiments, the antibody will be purified as measurable by at least three different methods: 1) to greater than 50% by weight of antibody as determined by the Lowry method, such as more than 75% by weight, or more than 85% by weight, or more than 95% by weight, or more than 99% by weight; 2) to a degree sufficient to obtain at least 10 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, such as at least 15 residues of sequence; or 3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or, alternatively, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the environment in which the antibody is produced will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step. In addition, the "isolated antibody" is substantially free of other antibodies having different antigenic specificities. An isolated antibody may, however, have some crossreactivity to other, related antigens.

[0042] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies that specifically bind to the same epitope, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. In contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that in one method of production they may be synthesized by a hybridoma culture, and thus are uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, in one embodiment, the monoclonal antibodies produced in accordance with the present disclosure may be made by the hybridoma method first described by Kohler and Milstein (Nature, 256:495 (1975)).

[0043] The monoclonal antibodies utilized in accordance with the present disclosure may be produced by any methodology known in the art including, but not limited to, a result of a deliberate immunization protocol; a result of an immune response that results in the production of antibodies naturally in the course of a disease or cancer; phage-derived antibodies; and the like. In addition to the hybridoma production method listed above, the monoclonal antibodies of the present disclosure may be produced by other various methods such as, but not limited to, recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567); isolation of antibody fragments from a phage display library (see, e.g., Clackson et al., Nature (1991) 352:624-628; and Marks et al., J. Mol. Biol. (1991) 222:581-597); as well as various other monoclonal antibody production techniques (see, e.g.,Harlow and Lane (1988) Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.)). Further, many monoclonal antibodies that may be utilized in the conjugates and methods disclosed or otherwise contemplated herein are widely commercially available, and therefore no further description thereof is deemed necessary.

[0044] Turning now to the inventive concepts, extracellular vesicles (EVs) are membrane vesicles that exist in body fluids that can be utilized for the diagnosis of various human and animal diseases. However, EVs have not been successfully used in the diagnosis of any bovine diseases. In the present disclosure, cattle-derived EVs (such as, but not limited to) serum-derived EVs were utilized to identify novel biomarkers for the diagnosis of bovine diseases. For example (but not by way of limitation), Bovine Respiratory Disease (BRD) is one of the leading causes of economic loss in the cattle industry, and there is no reliable method to correctly diagnose BRD. In the present disclosure, cattle-derived EVs were isolated from both healthy cattle and cattle exhibiting symptoms of BRD, and the proteome of these isolated EVs were characterized via mass spectrometry. EV samples from cattle with BRD were found to contain unique proteins derived from bacterial pathogens associated with BRD, while no such proteins were observed in the EVs isolated from healthy cattle. Besides bacterial pathogen proteins, a group of unique bovine proteins were also identified in EVs from sick cattle that were not present in the healthy cattle EVs. These unique pathogen-derived proteins and unique host-derived proteins can be utilized as novel biomarkers in assays for the diagnosis of cattle diseases such as (but not limited to) BRD. The biomarkers may be detected by any of the well-known detection methods known in the art or otherwise contemplated herein.

[0045] Certain non-limiting embodiments of the present disclosure include a method for diagnosing at least one disease in a bovine subject. In the method, a sample is obtained from the bovine subject, and extracellular vesicles (EVs) are isolated from the sample. The EVs are isolated to detect whether at least one protein biomarker is present in the isolated EVs; the presence of the at least one protein biomarker is indicative of disease.

[0046] The methods may be utilized to diagnose any cattle diseases for which at least one protein biomarker can be detected in EVs. Non-limiting examples of diseases include Bovine Respiratory Disease (BRD), gastrointestinal diarrhea, mastitis, paratuberculosis (Johne's Disease), bovine tuberculosis, parasitic diseases, metabolic and reproductive disorders, neurological Disease, and the like.

[0047] Any biological samples disclosed or otherwise contemplated herein may be utilized in accordance with the present disclosure. In a particular (but non-limiting) embodiment, the sample is a blood sample or a portion thereof, such as (but not limited to), whole blood, plasma, or serum.

[0048] The at least one biomarker may be from at least one pathogen (such as, but not limited to, at least a portion of a bacterial, viral, fungal, or protozoal pathogen protein).

[0049] Alternatively, and / or in addition thereto, the at least one biomarker may be from at least a portion of a bovine protein that is differentially expressed in diseased cattle compared to healthy cattle. For example, but not by way of limitation, the at least one biomarker may be detected in the EVs of the sample from the diseased subject but not substantially present in extracellular vesicles of healthy cattle. In other non-limiting embodiments, the at least one biomarker may be detected in the EVs of the sample from the diseased subject at a concentration that is substantially higher or lower than that detected in extracellular vesicles of healthy cattle. In yet other non-limiting embodiments, the at least one biomarker is substantially not detected in the EVs of the sample from the diseased subject but known to be present in extracellular vesicles of healthy cattle.

[0050] In certain particular (but non-limiting) embodiments, the methods include detection for multiple protein biomarkers, such as, but not limited to, at least two, three, four, five, six, seven, eight, nine, ten, or more protein biomarkers in the isolated EVs. For example, the method may screen for multiple types of microbial pathogens as well as for one or more differentially expressed host proteins.

[0051] In certain particular (but non-limiting) embodiments, the method may further include the step of administering at least one therapeutic composition to the subject if the at least one protein biomarker is detected. Non-limiting examples of therapeutic compositions that may be utilized in accordance with the present disclosure include antibiotics, antiviral compositions, and antibodies that specifically bind to a protein biomarker derived from a microbial pathogen.

[0052] Certain non-limiting embodiments of the present disclosure are directed to a method for diagnosing Bovine Respiratory Disease (BRD) in a bovine subject utilizing any of the method steps disclosed or otherwise contemplated herein. For example (but not by way of limitation), extracellular vesicles (EVs) may be isolated from a sample obtained from a bovine subject, and the EVs are analyzed for the presence of at least one protein biomarker. Detection of the presence of the at least one protein biomarker in the isolated EVs is indicative of BRD.

[0053] The at least one biomarker may be from at least one pathogen (such as, but not limited to, at least a portion of a bacterial, viral, fungal, or protozoal pathogen protein), or the at least one biomarker may be from at least a portion of a host bovine protein that is differentially expressed in diseased cattle compared to healthy cattle.

[0054] In certain particular (but non-limiting) embodiments, the at least one protein biomarker is derived from at least one bacterial pathogen protein. Non-limiting examples of bacteria that can cause BRD include Pasteurella multocida, Bibersteinia trehalose, Histophilus somni, Mycoplasma bovis, and the like, as well as any combinations thereof. Particular non-limiting examples of biomarkers associated with bacterial pathogens that can be utilized in accordance with the present disclosure include one or more of SEQ ID NOS:1-11.

[0055] In certain particular (but non-limiting) embodiments, the at least one protein biomarker is derived from at least one viral pathogen protein. Non-limiting examples of viruses that can cause BRD include bovine herpesvirus-1 (BHV-1, IBR), bovine viral diarrhea virus (BVD), bovine parainfluenza-3 (PI-3), bovine respiratory coronavirus (BRCV), bovine atadenovirus D, bovine atadenovirus E, bovine alphaherpesvirus 1, and the like, as well as any combinations thereof.

[0056] When the protein biomarker is at least a portion of a host bovine protein that is differentially expressed in BRD cattle compared to healthy cattle, the at least one biomarker may be detected in the EVs isolated from the sample but not substantially present in extracellular vesicles of healthy cattle. Non-limiting examples of host proteins that have been identified as being upregulated in BRD include ribosomal protein S6 kinase, xanthine dehydrogenase, myocilin, betahexosaminidase, Xaa-Pro dipeptidase, an Ig-like domain-containing protein, phospholipidtransporting ATPase, T-complex protein 1 subunit eta, myosin-6, and combinations thereof. Nonlimiting examples of biomarkers from host proteins that are unique to BRD cattle include SEQ ID NOS:12-105. Particular non-limiting examples of those biomarkers include SEQ ID NOS:12-14, 16, 22, 29, 32, 35, 39, and the like, as well as combinations thereof.

[0057] Alternatively, the at least one biomarker may be detected in the diseased sample at a concentration substantially higher or lower than detected in extracellular vesicles of healthy cattle.

[0058] In yet another alternative, the at least one biomarker may be substantially not detected in the sample but known to be present in extracellular vesicles of healthy cattle. That is, BRD causes inhibition of at least one protein produced in healthy cattle. Non-limiting examples of proteins that are downregulated in response to BRD include collagen alpha-l(l) chain, clathrin light chain,angiopoietin-1, stress-70 protein, and combinations thereof. Non-limiting examples of biomarkers present in the EVs of healthy cattle but not in the EVs of BRD cattle include SEQ ID NOS:106-195. Particular non-limiting examples of those biomarkers include SEQ ID NOS:115, 116, 119, 154, and the like, as well as any combinations thereof.

[0059] In certain particular (but non-limiting) embodiments, the method includes detection for multiple protein biomarkers associated with BRD, such as, but not limited to, at least two, three, four, five, six, seven, eight, nine, ten, or more protein biomarkers in the isolated EVs. For example, the method may screen for multiple types of microbial pathogens as well as for one or more differentially expressed host proteins.

[0060] In certain particular (but non-limiting) embodiments, the method may further include the step of administering at least one therapeutic composition to the subject if the at least one protein biomarker is detected. Non-limiting examples of therapeutic compositions that may be utilized in accordance with the present disclosure include antibiotics, antiviral compositions, and / or antibodies that specifically bind to a protein biomarker derived from a microbial pathogen.

[0061] A complex of microbes is routinely present in a cattle suffering from BRD; therefore, a cocktail or panel for detection of multiple biomarkers (both pathogen and differentially expressed host proteins) will allow for the determination of the specific microbes present. In addition, once the microbe(s) present are identified, the best treatment agent(s) to administer can be determined.

[0062] Certain non-limiting embodiments are further directed to a method of identifying at least one protein biomarker for a cattle disease. In the method, extracellular vesicles (EVs) are isolated from samples taken from a both (1) a plurality of diseased subjects and (2) a plurality of healthy cattle. Mass spectrometry analysis on the EVs from (1) and (2) are performed and compared to identify at least one differentially expressed protein that can function as a biomarker for the disease. The at least one differentially expressed protein is then analyzed against at least one protein database to identify the at least one differentially expressed protein.

[0063] Certain non-limiting embodiments of the present disclosure also contemplates methods of generating antibodies to any pathogen protein biomarkers disclosed herein or otherwise identified by the methods disclosed and contemplated herein. In the method, an antibodyproducing animal is immunized with at least a portion of at least one protein derived from a microbial pathogen, wherein the at least one protein has been identified as being present in extracellular vesicles (EVs) isolated from a serum sample of a diseased cattle subject (such as, butnot limited to, a cattle subject with BRD). Antibodies that specifically bind to the immunogen are then isolated from the animal.

[0064] The immunization and isolation steps may be performed by any methods known in the art orotherwise contemplated herein. In certain particular(but non-limiting) embodiments, the step of isolating antibodies further comprises the steps of: isolating antibody-producing spleen cells from the antibody-producing animal; selecting at least one antibody-producing spleen cell that secretes a monoclonal antibody that specifically binds to the immunogen; and preparing a hybrid cell line by fusing the selected antibody-producing spleen cell(s) from the antibody-producing animal with an appropriate fusion partner, whereby the hybrid cell line secretes the monoclonal antibody. The present disclosure also contemplates at least one antibody produced by the methods disclosed or otherwise contemplated herein.

[0065] The antibodies identified in this manner can be utilized as a diagnostic reagent for detection of the biomarkers and / or for use in treatment of the disease upon identification of the pathogen protein biomarkers within an individual cattle's (or a herd's) sample.

[0066] For example (but not by way of limitation), the antibodies may be utilized as a diagnostic agent for detection of BRD and / or as a therapeutic agent for treatment of BRD.

[0067] In particular (but non-limiting) embodiments, the immunogen comprises at least a portion of a microbial pathogen protein from a bacteria selected from the group consisting of Pasteurella multocida, Bibersteinia trehalose, Histophilus somni, Mycoplasma bovis, and combinations thereof. In a particular (but non-limiting) embodiment, the immunogen comprises one or more of SEQ ID NOS:1-11.

[0068] In particular (but non-limiting) embodiments, the immunogen comprises at least a portion of a viral pathogen protein from a virus selected from the group consisting of bovine herpesvirus-1 (BHV-1, IBR), bovine viral diarrhea virus (BVD), bovine parainfluenza-3 (PI-3), bovine respiratory coronavirus (BRCV), bovine atadenovirus D, bovine atadenovirus E, bovine alphaherpesvirus 1, and combinations thereof.

[0069] Certain non-limiting embodiments of the present disclosure also contemplate kits and systems that comprise at least one of any of the compositions, immunogens, and / or antibodies disclosed or otherwise contemplated herein.

[0070] For example (but not by way of limitation), the kit may be for performing any of the diagnostic methods disclosed or otherwise contemplated herein.

[0071] In particular (but non-limiting) embodiments, the kit may include at least one of any of the antibodies generated by the methods disclosed or otherwise contemplated herein. For example (but not byway of limitation), the kit may include multiple antibodies that detect different microbial pathogen biomarkers. Non-limiting examples include kits that contain at least two, three, four, five, six, seven, eight, nine, ten, or more antibodies that detect any of the biomarkers disclosed herein. In certain particular (but non-limiting) embodiments, the antibodies may be generated by any of the methods disclosed herein.

[0072] The kits may contain one or more additional agents therein, such as (but not limited to) one or more agents for performing the diagnostic assays and / or one or more therapeutic agents for treating any cattle positive for the biomarkers, as described in detail herein above.

[0073] The various components / reagents present in the kits may each be in separate containers / compartments, or various components / reagents can be combined in one or more containers / compartments, depending on the sterility, cross-reactivity, and stability of the components / reagents. In addition, the kits may be disposed in any packaging that allows the components present therein to function in accordance with the present disclosure. In certain nonlimiting embodiments, the kits further comprise a sealed packaging in which the components are disposed. In addition, the kits can further include a set of written instructions explaining how to use one or more components of the kit. A kit of this nature can be used in any of the methods described or otherwise contemplated herein.

[0074] In particular, the kits of the present disclosure are particularly of value for use in-field by cattle owners and ranchers. To that end, the kits may further comprise a device in which the reagents are disposed for ease of use in performing the methods disclosed herein. The device may further include a detection element for each biomarker being tested for ease of the operator in determining what type(s) of pathogen(s) is / are present. The kit or device may further include instructions for selecting one or more specific therapeutic agent(s) for treatment based on the pathogen(s) detected.EXAMPLES

[0075] Examples are provided hereinbelow. However, the present disclosure is to be understood to not be limited in its application to the specific experimentation, results, andlaboratory procedures disclosed herein after. Rather, the Examples are simply provided as one of various embodiments and are meant to be exemplary, not exhaustive.

[0076] In this Example, EVs were collected from the sera of healthy cattle and those with BRD symptoms, and the protein profile of the isolated EVs was determined. The results showed that some EV samples isolated from sick cattle contained proteins from known BRD-associated bacterial pathogens, which were completely absent in EVs from healthy cattle. In addition, we identified unique bovine proteins in the EV samples of cattle with BRD symptoms that were not found in the EVs of healthy cattle. In summary, our data suggest that proteins in bovine serum-derived EVs can be analyzed to identify bovine proteins indicative of BRD and proteins from pathogens responsible for the disease.

[0077] Results

[0078] Characterization of EVs isolated from healthy and sick cattle. To determine if EVs from sick cattle exhibiting symptoms of BRD carried BRD-associated pathogen protein biomarkers, we compared the proteomic profiles of EVs isolated from the serum of healthy cattle and those diagnosed with BRD via DART (Centeno-Martinez et al., Animal Microbiome (2022) 4:15; Wilson et aL, J Anim Sci (2015) 93:3661-3674). EVs isolated from the serum of healthy cattle or cattle with BRD have a similar size distribution pattern (FIG. 1, Panel A), yet greater EV yield for EVs isolated from the serum of cattle with BRD (FIG. 1, Panel B). Protein abundance assays indicated that EVs from healthy cattle and sick cattle carried similar levels of total proteins (FIG. 1, Panel C).

[0079] EVs from sick cattle carry bacterial pathogen proteins. In a BRD EV sample dependent fashion, proteins were identified from multiple BRD-associated bacterial pathogens, including Pasteurella multocida, Bibersteinia trehalose, Histophilus somni, and Mycoplasma bovis (Table 1). In EVs from sick cattle #6, proteins of all the bacterial pathogens mentioned above were detected. In EVs from sick cattle #3, proteins from two bacterial species were detected: Bibersteinia trehalose and Histophilus somni. In EVs from sick cattle #2, a protein was detected from Bibersteinia trehalose. The pathogen peptides detected aligned to bacterial proteins (Table 1) and did not map to any bovine proteins, indicating these peptides are from bacterial pathogens. No pathogen proteins were detected in EVs isolated from sick cattle # 1, 4, 5 and 7, or in EVs from all healthy cattle. Unexpectedly, no viral proteins were observed in any EV samples investigated.

[0080] In addition to pathogen proteins, EVs from sick cattle or healthy cattle both contain unique bovine proteins. In an EV sample dependent fashion, 94 bovine proteins in EVs from sickcattle were identified that were not detected in healthy cattle EVs (Table 2). Bovine ribosomal protein S6 kinase was detected in 4 of the 7 sick cattle EV samples and 8 unique bovine proteins (xanthine dehydrogenase, myocilin, beta-hexosaminidase, Xaa-Pro dipeptidase, an Ig-like domaincontaining protein; phospholipid-transporting ATPase, T-complex protein 1 subunit eta, and myosin-6) were detected in 3 sick cattle EV samples (FIG. 2, Panel A). There were 24 unique bovine proteins that were detected in 2 sick cattle EV samples and 61 unique bovine proteins only in 1 sick cattle EV sample (FIG. 2, Panel A).

[0081] Bovine proteins that were unique in EVs from healthy cattle were also analyzed. As shown in Table 3, in an EV sample dependent fashion, 91 unique bovine proteins were identified in healthy cattle EV samples that were not found in sick cattle EV samples. Among these 91 bovine proteins, two proteins, collagen alpha-l(l) chain and clathrin light chain, were detected in 4 out of 5 healthy cattle EV samples (FIG. 2, Panel B). Anothertwo bovine proteins, angiopoietin-1 and stress-70 protein, were detected in three healthy cattle EV samples. There were another 22 and 65 unique bovine proteins that were detected in 2 and 1 healthy cattle EV samples, respectively (FIG. 2, Panel B).

[0082] Discussion

[0083] This Example provides evidence that the protein profile in serum EVs differs between healthy cattle and those with BRD. This is similar to the observations in EVs from human patients with infectious diseases compared to healthy individuals (Schorey et al., EMBO reports (2021) 16:24-43; Schorey et aL, EMBO reports (2015) 16:24-43). Microbial pathogen proteins in EVs can be excellent biomarkers for the diagnosis of infectious diseases in humans and animals (Kotey et al. Microorganisms (2024) 12:2656; Schorey et al., Journal of Cell Science (2021) 134). This study revealed that EVs from the cattle with BRD contain proteins derived from bacterial pathogens implicated in BRD, including Pasteurella multocida, Bibersteinia trehalose, Histophilus somni, and Mycoplasma bovis (Gaudino et al., Veterinary Research (2022) 53:70). While pathogen proteins were only detected in 3 of 7 cattle with BRD symptoms, the results indicate that the proteins within cattle serum EVs can be used to distinguish BRD cattle from healthy cattle. Interestingly, besides bacterial pathogen proteins, a list of unique bovine proteins in EVs isolated from cattle with BRD symptoms or healthy cattle were also detected, indicating that host-derived proteins could also be used to detect cattle with BRD.

[0084] In conclusion, the data presented herein indicate that disease states can influence theprotein composition of EVs, which may be a reflection of the pathological processes occurring in humans and animals. The variation in any one or a number of the unique bovine and pathogen EV proteins observed in this Example can be used as a molecular biomarker for BRD diagnosis. Furthermore, the approach described herein can also be used to identify the presence of specific BRD pathogens and thereby help focus therapies and interventions aimed at managing BRD in cattle.

[0085] Materials and Methods

[0086] Animals. All animal experiments were approved by the Institutional Animal Care and Use Committees (IACUC) of Oklahoma State University (IACUC-22-39; BW).

[0087] Cattle Serum Harvest. Cattle blood samples were collected via jugular vein puncture in 10 ml vacutainer tubes (BD Vacutainer; Thermo Fisher Scientific, Waltham, MA) on the appropriate days from a subset of animals (bull). All blood samples were collected in the morning, immediately prior to feeding at approximately 0600 h for defined sampling days and between 0700 h and 1000 h for any animals pulled for treatment evaluation. After blood was collected, blood samples were briefly chilled on ice and then refrigerated at 4°C until serum was harvested. Serum was obtained by centrifuging the whole blood samples at 2,100 x g for 20 min at 5°C (Sorvall RC6; Thermo Scientific, Waltham, MA). Upon collection of serum, samples were aliquoted into 2 mL microcentrifuge tubes for each animal and timepoint and stored at -80°C until analyses were conducted.

[0088] Cattle EV isolation. Serum-derived EVs were isolated from 1 ml of bovine serum as we described previously (Guthrie et aL, Journal of Proteome Research (2025)). Briefly, serum was centrifuged at 13,000 rpm for 30 min at 4°C, and then the pellet was washed with ice-cold PBS three times and spun down at 13,000 rpm for 30 min at 4°C. The resulting EV pellet was resuspended in ice-cold PBS and stored at -80°C until use. EV size and distribution was determined using a NanoSight NS300 (Malvern Panalytical, UK) as previously described (Vermeire et al., Proteomics (2024) e2300332). The protein concentration of EVs samples were determined with Pierce™ BCA Protein Assay Kits (Cat. No. 23227; ThermoFischer Scientific).

[0089] Proteomic analysis for cattle EVs. The EV samples from healthy and sick cattle were processed for mass spectrometry analysis as we described previously (Kotey et al. Microorganisms (2024) 12:2656; Vermeire et al., (2024) Proteomics, e202400181) in the proteomics core facility at Oklahoma State University in Stillwater, OK. Raw data were analyzed against a database consisting of 37,519 bovine proteins (UniProt Taxon ID: 9913; Bos taurus) and 6 bacterial and 8 viral proteindatasets (Gaudino et al., Veterinary Research (2022) 53:70) using Perseus (version 2.0.10.0). The following default options in MaxQuant were used: i) Fixed modification: Carbamidomethyl of cysteine (Cys), and ii) Variable modifications: oxidation of methionine (Met), acetylation of protein N-termini, and chemical cyclization of glutamine (Gin) residues to pyroglutamate if they are at the n-terminus of the peptide.

[0090] Statistical Analysis. Data were analyzed using PRISM GraphPad (Version 9.5.0) via two-tailed Student's t-test; p < 0.05 was considered significant.NON-LIMITING ILLUSTRATIVE EMBODIMENTS

[0091] Illustrative embodiment 1. A method for diagnosing at least one disease in a bovine subject, the method comprising: obtaining a sample from the bovine subject; isolating extracellular vesicles (EVs) from the sample; and detecting the presence of at least one protein biomarker in the isolated EVs, wherein the presence of the at least one protein biomarker is indicative of disease.

[0092] Illustrative embodiment 2. The method of Illustrative embodiment 1, wherein the sample is a serum sample.

[0093] Illustrative embodiment 2a. The method of Illustrative embodiment 1 or 2, wherein the at least one protein biomarker is at least a portion of at least one microbial pathogen protein.

[0094] Illustrative embodiment 3. The method of Illustrative embodiment 1 or 2, wherein the at least one protein biomarker is at least a portion of at least one bacterial pathogen protein.

[0095] Illustrative embodiment 4. The method of Illustrative embodiment 1 or 2, wherein the at least one protein biomarker is at least a portion of at least one viral pathogen protein.

[0096] Illustrative embodiment 5. The method of any of Illustrative embodiments 1-4, wherein the at least one protein biomarker is at least a portion of a bovine protein that is differentially expressed in diseased cattle compared to healthy cattle.

[0097] Illustrative embodiment 6. The method of Illustrative embodiment 5, wherein the at least one biomarker is detected in the sample and is not substantially present in extracellular vesicles of healthy cattle.

[0098] Illustrative embodiment 7. The method of any of Illustrative embodiments 1-6, wherein the at least one biomarker is detected in the sample at a concentration substantially higher than detected in extracellular vesicles of healthy cattle.

[0099] Illustrative embodiment 8. The method of any of Illustrative embodiments 1-6, wherein the at least one biomarker is detected in the sample at a concentration substantially lower than detected in extracellular vesicles of healthy cattle.

[0100] Illustrative embodiment 9. The method of any of Illustrative embodiments 1-6, wherein the at least one biomarker is substantially not detected in the sample but known to be present in extracellular vesicles of healthy cattle.

[0101] Illustrative embodiment 10. The method of any of Illustrative embodiments 1-9, wherein the detecting step is further defined as detecting the presence of at least two protein biomarkers in the isolated EVs.

[0102] Illustrative embodiment 11. The method of any one of Illustrative embodiments 1-10, further comprising the step of administering at least one therapeutic composition to the subject if the at least one protein biomarker is detected.

[0103] Illustrative embodiment 11a. The method of Illustrative embodiment 11, wherein the therapeutic composition comprises at least one of an antibiotic and an antiviral agent.

[0104] Illustrative embodiment 12. The method of Illustrative embodiment 11 or 11a, wherein the therapeutic composition comprises at least one antibody that specifically binds to the at least one protein biomarker derived from a microbial pathogen.

[0105] Illustrative embodiment 13. The method of any of Illustrative embodiments 1-12, wherein the at least one disease is selected from the group consisting of Bovine Respiratory Disease (BRD), gastrointestinal diarrhea, mastitis, paratuberculosis (Johne's Disease), bovine tuberculosis, parasitic diseases, metabolic and reproductive disorders, neurological Disease, and combinations thereof.

[0106] Illustrative embodiment 14. A method for diagnosing Bovine Respiratory Disease (BRD) in a bovine subject, the method comprising: obtaining a sample from the bovine subject; isolating extracellular vesicles (EVs) from the sample; and detecting the presence of at least one protein biomarker in the isolated EVs, wherein the presence of the at least one protein biomarker is indicative of BRD.

[0107] Illustrative embodiment 15. The method of Illustrative embodiment 14, wherein the sample is a serum sample.

[0108] Illustrative embodiment 16. The method of Illustrative embodiment 14 or 15, wherein the at least one protein biomarker is at least a portion of at least one microbial pathogen protein.

[0109] Illustrative embodiment 16a. The method of Illustrative embodiment 16, wherein the at least one microbial pathogen protein comprises at least one bacterial pathogen protein.

[0110] Illustrative embodiment 17. The method of Illustrative embodiment 16, wherein the at least one bacterial pathogen protein is derived from at least one pathogen selected from the group consisting of Pasteurella multocida, Bibersteinia trehalose, Histophilus somni, Mycoplasma bovis, and combinations thereof.

[0111] Illustrative embodiment 18. The method of Illustrative embodiment 16, wherein the at least one microbial pathogen protein comprises at least one viral pathogen protein.

[0112] Illustrative embodiment 19. The method of Illustrative embodiment 18, wherein the at least one viral pathogen protein is derived from at least one pathogen selected from the group consisting of bovine herpesvirus-1 (BHV-1, IBR), bovine viral diarrhea virus (BVD), bovine parainfluenza-3 (PI-3), bovine respiratory coronavirus (BRCV), bovine atadenovirus D, bovine atadenovirus E, bovine alphaherpesvirus 1, and combinations thereof.

[0113] Illustrative embodiment 20. The method of Illustrative embodiment 18 or 19, wherein the at least one protein biomarker comprises at least one of SEQ ID NOS:1-11.

[0114] Illustrative embodiment 21. The method of any of Illustrative embodiments 14-20, wherein the at least one protein biomarker is at least a portion of a bovine protein that is differentially expressed in BRD cattle compared to healthy cattle.

[0115] Illustrative embodiment 22. The method of Illustrative embodiment 21, wherein the at least one biomarker is detected in the sample and is not substantially present in extracellular vesicles of healthy cattle.

[0116] Illustrative embodiment 23. The method of Illustrative embodiment 22, wherein the at least one biomarker is selected from the group consisting of at least one of SEQ ID NOS:12-105.

[0117] Illustrative embodiment 24. The method of any of Illustrative embodiments 14-23, wherein the at least one biomarker is derived from a bovine protein selected from the group consisting of ribosomal protein S6 kinase, xanthine dehydrogenase, myocilin, beta-hexosaminidase, Xaa-Pro dipeptidase, an Ig-like domain-containing protein, phospholipid-transporting ATPase, T-complex protein 1 subunit eta, myosin-6, and combinations thereof.

[0118] Illustrative embodiment 25. The method of any of Illustrative embodiments 14-24, wherein the at least one biomarker is selected from the group consisting of SEQ ID NOS:12-14, 16, 22, 29, 32, 35, 39, and combinations thereof.

[0119] Illustrative embodiment 26. The method of any of Illustrative embodiments 14-25, wherein the at least one biomarker is detected in the sample at a concentration substantially higher than detected in extracellular vesicles of healthy cattle.

[0120] Illustrative embodiment 27. The method of any of Illustrative embodiments 14-26, wherein the at least one biomarker is detected in the sample at a concentration substantially lower than detected in extracellular vesicles of healthy cattle.

[0121] Illustrative embodiment 28. The method of any of Illustrative embodiments 14-27, wherein the at least one biomarker is substantially not detected in the sample but known to be present in extracellular vesicles of healthy cattle.

[0122] Illustrative embodiment 29. The method of Illustrative embodiment 28, wherein the at least one biomarker is selected from the group consisting of at least one of SEQ ID NOS:106-196.

[0123] Illustrative embodiment 30. The method of any of Illustrative embodiments 14-29, wherein the at least one protein from which the biomarker is derived is selected from the group consisting of collagen alpha-l(l) chain, clathrin light chain, angiopoietin-1, stress-70 protein, and combinations thereof.

[0124] Illustrative embodiment 31. The method of any of Illustrative embodiments 14-30, wherein the at least one biomarker is selected from the group consisting of SEQ ID NOS:115, 116, 119, 154, and combinations thereof.

[0125] Illustrative embodiment 32. The method of any of Illustrative embodiments 1-31, wherein the detecting step is further defined as detecting the presence of at least two protein biomarkers in the isolated EVs.

[0126] Illustrative embodiment 32a. The method of any of Illustrative embodiments 1-32, wherein the detecting step is further defined as detecting the presence of at least three protein biomarkers in the isolated EVs.

[0127] Illustrative embodiment 32b. The method of any of Illustrative embodiments l-32a, wherein the detecting step is further defined as detecting the presence of at least four protein biomarkers in the isolated EVs.

[0128] Illustrative embodiment 32c. The method of any of Illustrative embodiments l-32b, wherein the detecting step is further defined as detecting the presence of at least five protein biomarkers in the isolated EVs.

[0129] Illustrative embodiment 32d. The method of any of Illustrative embodiments l-32c, wherein the detecting step is further defined as detecting the presence of at least six protein biomarkers in the isolated EVs.

[0130] Illustrative embodiment 32e. The method of any of Illustrative embodiments l-32d, wherein the detecting step is further defined as detecting the presence of at least seven protein biomarkers in the isolated EVs.

[0131] Illustrative embodiment 32f. The method of any of Illustrative embodiments l-32e, wherein the detecting step is further defined as detecting the presence of at least eight protein biomarkers in the isolated EVs.

[0132] Illustrative embodiment 33. The method of any one of Illustrative embodiments 1-32, further comprising the step of administering at least one therapeutic composition to the subject if the at least one protein biomarker is detected.

[0133] Illustrative embodiment 33a. The method of Illustrative embodiment 33, wherein the at least one therapeutic composition comprises at least one of an antibiotic and an antiviral agent.

[0134] Illustrative embodiment 34. The method of Illustrative embodiment 33 or 33a, wherein the at least one therapeutic composition comprises at least one antibody that specifically binds to the at least one protein biomarker derived from a microbial pathogen.

[0135] Illustrative embodiment 35. A method of identifying at least one protein biomarker for a cattle disease, the method comprising the steps of: (1) isolating extracellular vesicles (EVs) from samples taken from a plurality of diseased subjects; (2) isolating EVs from samples taken from a plurality of healthy cattle; (3) performing mass spectrometry analysis on the EVs from (1) and (2); (4) comparing the mass spectrometry analyses from the diseased subjects to the healthy cattle to identify at least one differentially expressed protein that can function as a biomarker for the disease; and (5) analyzing the at least one differentially expressed protein against at least one protein database to identify the at least one differentially expressed protein.

[0136] Illustrative embodiment 36. A method of generating an antibody, the method comprising the steps of: immunizing an antibody-producing animal with at least a portion of at least one protein derived from a microbial pathogen, wherein the at least one protein has been identified as being present in a serum extracellular vesicle sample of a subject with BRD; and isolating antibodies that specifically bind to the immunogen from the animal.

[0137] Illustrative embodiment 37. The method of Illustrative embodiment 36, wherein the antibody is further defined as a diagnostic agent for detection of BRD.

[0138] Illustrative embodiment 38. The method of Illustrative embodiment 36 or 37, wherein the antibody is further defined as a therapeutic agent for treatment of BRD.

[0139] Illustrative embodiment 39. The method of any of Illustrative embodiments 36-38, wherein the microbial pathogen is a bacterial pathogen selected from the group consisting of Pasteurella multocida, Bibersteinia trehalose, Histophilus somni, Mycoplasma bovis, and combinations thereof.

[0140] Illustrative embodiment 40. The method of any of Illustrative embodiments 36-39, wherein the antibody-producing animal is immunized with at least one peptide comprising at least one of SEQ ID NOS:1-11.

[0141] Illustrative embodiment 41. The method of any of Illustrative embodiments 36-40, wherein the microbial pathogen is a viral pathogen selected from the group consisting of bovine herpesvirus-1 (BHV-1, IBR), bovine viral diarrhea virus (BVD), bovine parainfluenza-3 (PI-3), bovine respiratory coronavirus (BRCV), bovine atadenovirus D, bovine atadenovirus E, bovine alphaherpesvirus 1, and combinations thereof.

[0142] Illustrative embodiment 42. A kit for performing the method of any of Illustrative embodiments 1-35.

[0143] Illustrative embodiment 43. A kit, comprising at least one antibody generated by the method of any of Illustrative embodiments 36-41.

[0144] Illustrative embodiment 44. The kit of Illustrative embodiment 43, further defined as comprising at least two antibodies generated by the method of any of Illustrative embodiments 36-41.

[0145] Illustrative embodiment 45. The kit of Illustrative embodiment 43, further defined as comprising at least three antibodies generated by the method of any of Illustrative embodiments 36-41.

[0146] Illustrative embodiment 46. The kit of Illustrative embodiment 43, further defined as comprising at least four antibodies generated by the method of any of Illustrative embodiments 36- 41.

[0147] Illustrative embodiment 47. The kit of Illustrative embodiment 43, further defined as comprising at least five antibodies generated by the method of any of Illustrative embodiments 36- 41.

[0148] Illustrative embodiment 48. The kit of Illustrative embodiment 43, further defined as comprising at least six antibodies generated by the method of any of Illustrative embodiments 36-41.

[0149] Illustrative embodiment 49. The kit of Illustrative embodiment 43, further defined as comprising at least seven antibodies generated by the method of any of Illustrative embodiments 36-41.

[0150] Illustrative embodiment 50. The kit of Illustrative embodiment 43, further defined as comprising at least eight antibodies generated by the method of any of Illustrative embodiments 36-41.

[0151] Thus, in accordance with the present disclosure, there have been provided compositions, kits, and systems, as well as methods of producing and using same, which fully satisfy the objectives and advantages set forth hereinabove. Although the present disclosure has been described in conjunction with the specific drawings, experimentation, results, and language set forth hereinabove, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications, and variations that fall within the spirit and broad scope of the present disclosure.

Claims

CLAIMS1. A method for diagnosing Bovine Respiratory Disease (BRD) in a bovine subject, the method comprising:obtaining a sample from the bovine subject;isolating extracellular vesicles (EVs) from the sample; anddetecting the presence of at least one protein biomarker in the isolated EVs, wherein the presence of the at least one protein biomarker is indicative of BRD.

2. The method of claim 1, wherein the sample is a serum sample.

3. The method of claim 1, wherein the at least one protein biomarker is at least a portion of at least one microbial pathogen protein.

4. The method of claim 3, wherein the at least one microbial pathogen protein comprises a bacterial pathogen protein.

5. The method of claim 4, wherein the at least one bacterial pathogen protein is derived from at least one pathogen selected from the group consisting of Pasteurella multocida, Bibersteinia trehalose, Histophilus somni, Mycoplasma bovis, and combinations thereof.

6. The method of claim 4, wherein the at least one protein biomarker comprises at least one of SEQ ID NOS:1-11.

7. The method of claim 1, wherein the at least one protein biomarker is at least a portion of a bovine protein that is differentially expressed in BRD cattle compared to healthy cattle.

8. The method of claim 7, wherein the at least one protein biomarker is detected in the sample and is not substantially present in extracellular vesicles of healthy cattle.

9. The method of claim 8, wherein the at least one biomarker is selected from the group consisting of at least one of SEQ ID NOS:12-105.

10. The method of claim 8, wherein the at least one protein biomarker is derived from a bovine protein selected from the group consisting of ribosomal protein S6 kinase, xanthine dehydrogenase, myocilin, beta-hexosaminidase, Xaa-Pro dipeptidase, an Ig-like domain-containing protein, phospholipid-transporting ATPase, T-complex protein 1 subunit eta, myosin-6, and combinations thereof.

11. The method of claim 10, wherein the at least one biomarker is selected from the group consisting of SEQ ID NOS:12-14, 16, 22, 29, 32, 35, 39, and combinations thereof.

12. The method of claim 1, wherein the detecting step is further defined as detecting the presence of at least two protein biomarkers in the isolated EVs.

13. The method of any one of claims 1-12, further comprising the step of administering at least one therapeutic composition to the subject if the at least one protein biomarker is detected.

14. The method of claim 13, wherein the therapeutic composition comprises at least one of an antibiotic and an antiviral agent.

15. The method of claim 13, wherein the therapeutic composition comprises at least one antibody that specifically binds to the at least one protein derived from a microbial pathogen.

16. A method of identifying at least one protein biomarker for a cattle disease, the method comprising the steps of:(1) isolating extracellular vesicles (EVs) from samples taken from a plurality of diseased subjects;(2) isolating EVs from samples taken from a plurality of healthy cattle;(3) performing mass spectrometry analysis on the EVs from (1) and (2);(4) comparing the mass spectrometry analyses from the diseased subjects to the healthy cattle to identify at least one differentially expressed protein that can function as a biomarker for the disease; and(5) analyzing the at least one differentially expressed protein against at least one protein database to identify the at least one differentially expressed protein.

17. A method of generating an antibody, the method comprising the steps of:immunizing an antibody-producing animal with at least a portion of at least one protein derived from a microbial pathogen, wherein the at least one protein has been identified as being present in a serum extracellular vesicle sample of a subject with BRD; andisolating antibodies that specifically bind to the immunogen from the animal.

18. The method of claim 17, wherein the microbial pathogen is a bacterial pathogen.

19. The method of claim 18, wherein the bacterial pathogen is selected from the group consisting of Pasteurella multocida, Bibersteinia trehalose, Histophilus somni, Mycoplasma bovis, and combinations thereof.

20. The method of claim 19, wherein the antibody-producing animal is immunized with at least one peptide comprising at least one of SEQ. ID NOS:1-11.